Reports Q4 revenue $105.5M, consensus $100.96M. “Our record fourth quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond,” said Thomas Burns, Glaukos (GKOS) chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Notable companies reporting after market close
- Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz
- Electronic Arts initiated, Workday downgraded: Wall Street’s top analyst calls
- Mizuho upgrades Glaukos to Outperform on ‘bullish’ iDose checks
- Glaukos upgraded to Outperform from Neutral at Mizuho